Table 2

Clinical characteristics and brain volumes at MRI-1 and MRI-2 and the annualised atrophy rate in patients with MS and AQP4+NMOSD between MRI-1 and MRI-2 in study 1

AQP4+NMOSD (n=36)RRMS (n=60)p value
ΔEDSS (MRI-2 – MRI-1)0.0 (0.0) (–2.0–3.5)0.0 (0.19) (–3.0–2.5)0.81
Years from MRI-1 to MRI-23.1 (2.5) (1.0–6.3)2.2 (1.8) (1.0–6.1)0.045*
ARR between MRI-1 and MRI-20.0 (0.0) (0.0–0.88)0.0 (0.0) (0.0–1.5)0.56
At MRI-1
 ICV*10-3 (mL)1.3 (0.12) (1.2–1.6)1.4 (0.14) (1.1–1.7)0.034*
 NLV (mL)1.0 (5.2) (0.0–33.2)6.4 (10.3) (0.45–46.7)<0.001*
 NGV*10-3 (mL)0.43 (0.063) (0.32–0.49)0.44 (0.058) (0.32–0.50)0.47
 NWV*10-3 (mL)0.31 (0.029) (0.22–0.34)0.29 (0.033) (0.23–0.34)0.007*
 NBV*10-3 (mL)0.75 (0.070) (0.62–0.81)0.73 (0.085) (0.59–0.80)0.61
At MRI-2
 ICV*10-3 (mL)1.3 (0.12) (1.2–1.6)1.4 (0.14) (1.1–1.7)0.068
 NLV (mL)2.4 (9.0) (0.0–142)6.6 (10.3) (0.0–187)0.019*
 NGV*10-3 (mL)0.43 (0.053) (0.31–0.49)0.44 (0.060) (0.32–0.50)0.5
 NWV*10-3 (mL)0.31 (0.033) (0.22–0.34)0.29 (0.029) (0.22–0.34)0.007*
 NBV*10-3 (mL)0.74 (0.074) (0.60–0.80)0.72 (0.088) (0.58–0.80)0.43
Annualised atrophy rate
 NGV (%)0.50 (1.1) (–2.4–4.9)0.36 (1.4) (–2.5–5.7)0.96
 NWV (%)0.21 (1.5) (–6.2–4.5)0.33 (2.0) (–3.6–6.3)0.72
 NBV (%)0.47 (0.75) (–0.57–3.0)0.48 (0.85) (–1.3–3.4)0.47

  • Data are presented as median number (%) or (IQR) (range). *p<0.05.

  • Annualised atrophy rate of X is defined as follows: Embedded Image , X= NGV, NWV or NBV.

  • ΔEDSS= EDSS at MRI-2 minus EDSS at MRI-1.

  • AQP4+NMOSD, anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder disease; EDSS, Kurtzke’s Expanded Disability Status Scale; ICV, intracranial volume; NBV, normalised brain volume; NGV, normalised grey matter volume; NLV, normalised lesion volume; NWV, normalised white matter volume.